Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Eligab Tx LLC is focused on the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 2 pending office actions. Both of these actions are being handled by 1 distinct examiner within 1 distinct art unit, indicating a high level of centralization in the company's prosecution. This suggests that the pending applications are likely related to the same core technology or are part of a particular patent family being reviewed by the same specialist.
The busiest examiner for Eligab Tx LLC is ALLEN, SARAH ELIZABETH, who is responsible for 2 pending office actions. This examiner manages the company's active prosecution. Such concentration allows for a consistent dialogue with the examiner but also means the portfolio's immediate progress is tied to a specific individual's assessment. Practitioners can use this to their advantage by ensuring that arguments made in one application are consistent with the other. However, the lack of examiner diversity means that any negative trends in this specific art unit will affect the entire pending portfolio. A proactive approach in addressing the examiner's concerns will be vital for maintaining the momentum of the company's patenting efforts in the pharmaceutical space.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, SARAH ELIZABETH | 2 | 56.7% | +33.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18336617 | ANTISENSE OLIGONUCLEOTIDES INCREASING FOXG1 EXPRESSION | ALLEN, SARAH ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18336617 | ANTISENSE OLIGONUCLEOTIDES INCREASING FOXG1 EXPRESSION | ALLEN, SARAH ELIZABETH | — |
| 18336603 | ANTISENSE OLIGONUCLEOTIDES TARGETING FOXG1 | ALLEN, SARAH ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1637 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18336617 | ANTISENSE OLIGONUCLEOTIDES INCREASING FOXG1 EXPRESSION | ALLEN, SARAH ELIZABETH | 1637 | §103§112 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18336603 | ANTISENSE OLIGONUCLEOTIDES TARGETING FOXG1 | ALLEN, SARAH ELIZABETH | 1637 | §112 | Non-Final OA | — | Pending | Jun 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEligab Tx LLC has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sarah Elizabeth Allen has the most, with 2 of Eligab Tx LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
